Table 1.

Clinical trials (clinicaltrials.gov).

1 NCT00274846; Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia

2 NCT00328861; Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer

3 NCT01181258; Pentostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies

4 NCT01385423; Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)

5 NCT01875601; NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors

6 NCT01212341; Allogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid Tumor

7 NCT03415100; Pilot Study of NKG2D-Ligand Targeted CAR-NK Cells in Patients With Metastatic Solid Tumours

8 NCT03940820; Clinical Research of ROBO1 Specific CAR-NK Cells on Patients With Solid Tumors

9 NCT02643550; Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

10 NCT03088059; Biomarker-based Study in R/M SCCHN

11 NCT02671435; A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

12 NCT02459301; A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies

13 NCT02671435; A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

14 NCT01968109; An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

15 NCT03470922; A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

16 NCT02658981; Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)

NKG2D: Natural Killer Group 2D; CAR: Chimeric Antigen Receptor; ROBO1: roundabout-1; SCCHN: squamous cell carcinoma of the head and neck; LAG: Lymphocyte-activation gene 3.